Pleiotropic Effects of GLP-1. Cardiovascular Evidence of Effectiveness
Open Access PP
650
Type 2 Diabetes Treated for at Least 3 Years,” Current
Medical Research and Opinion, Vol. 24, 2008, pp. 275-
286.
[16] A. Garber, R. Henry, R. Ratner, et al., “Liraglutide versus
Glimepiride Monotherapy for Type 2 Diabetes (LEAD-3
Mono): A Randomised 52 Weeks, Phase III, Double-
Blind, Paralle-Treatment Trial,” Lancet, Vol. 373, No.
9662, 2009, pp. 473-481.
http://dx.doi.org/10.2337/diacare.28.5.1083
[17] M. Nauck, A. Frid, K. Hermansen, et al., “Efficacy and
Safesty Comparison of Liraglutide, Glimpiride and Placebo
All in Combination with Metformin in Type 2 Diabetes,”
Diabetes Care, Vol. 32, No. 1, 2009, pp. 84-90.
http://dx.doi.org/10.2337/dc08-1355
[18] B. Zinman, J. Gerich, J. B. Buse, et al., “Efficacy and
Safety of the Human GLP-1 Analog Liraglutide in Com-
bination with Metformin and TZD in Patients with Type 2
Diabetes (LEAD-4-Met + TZD),” Diabetes Care, Vol. 32,
2009, pp. 1224-1230.
http://dx.doi.org/10.2337/dc08-2124
[19] D. Russell-Jones, A. Vaag, O. Schmitz, et al., “Liraglu-
tide vs Insulin Glargine and Placebo in Combination with
Metformin and Sulphonylurea Therapy in Type 2 Diabe-
tes Mellitus: A Randomised Controlled Trial(LEAD-5
met + SU),” Diabetología, Vol. 52, No. 10, 2009, p. 2046.
http://dx.doi.org/10.1007/s00125-009-1472-y
[20] J. Buse, J. Rosenstock, G. Sesti, et al., “A Study of Two
Glucagon-Like Peptide-1 Receptor Agonists for the
Treatment of Type 2 Diabetes: Liraglutide Once Daily
Compared with Exenatide Twice Daily in a Randomised
26 Weeks, Open-Label Trial(LEAD-6),” Lancet, Vol. 374,
2009, pp. 39-47.
http://dx.doi.org/10.1016/S0140-6736(09)60659-0
[21] T. Okerso, P. Yan, A. Stonehouse and R. Brodows, “Ef-
fects of Exenatide on Systolic Lood Pressure in Subjects
with Type 2 Diabetes,” American Journal of Hyperten-
sion, Vol. 23, No. 3, 2010, pp. 334-339.
http://dx.doi.org/10.1038/ajh.2009.245
[22] L. Blonde and D. Russell-Jones, “The Safety and Efficacy
of Liraglutide with or without Oral Antidiabetic Drug
Therapy in Type 2 Diabetes: An Overview of the LEAD
1-5 Studies,” Diabetes, Obesity and Metabolism, Vol. 11,
Suppl. 3, 2009, pp. 26-34.
http://dx.doi.org/10.1111/j.1463-1326.2009.01075.x
[23] M. Arakawa, T. Mita, K. Azuma, C. Ebato, H. Goto, T.
Nomiyama, Y. Fujitani, T. Horise, R. Kawamori and H.
Watada, “Inhibition of Monocyt Adhsion to Endothelial
Cells and Attenuation of Atherosclerotic Lesion by a
Glucagon-Like Peptide-1 Receptor Agonist, Exendin-4,”
Diabetes, Vol. 59, No. 4, 2010, pp. 1030-1037.
http://dx.doi.org/10.2337/db09-1694
[24] A. Basu, N. Charkoudian, W. Schrage, R. A. Rizza, R.
Basu and M. J. Joyner, “Benefial Effects of GLP-1 on
Endothelial Function in Humans: Dampening by Gly-
buride but Not by Glimepiride,” Endocrinology and Me-
tabolism—American Journal of Physiology, Vol. 293,
2005, pp. E1289-E1295.
[25] T. Nyström, M. K. Gutniak, F. Zhan, J. J. Holst, B. Ahrén
and A. Sjöholm, “Effects of Glucagon-Like Peptide-1 on
Endothelial Function in Type 2 Diabetes Patients with
Stable Coronary Artery Disease,” Endocrinology and
Metabolism—American Journal of Physiology, Vol. 287,
2004, pp. E1209-E1215.
[26] S. Ozyazgan, N. Kutluta, S. Afsar, S. B. Ozdas and A. G.
Akkan, “Effect of Glucagon-Like Peptide-1(7-36) and
Exendin-4 on the Vascular Reactivity in Streptozotocin/
Nicotinamide-Induced Diabetic Rats,” Pharmacology, Vol.
74, No. 3, 2005, pp. 119-126.
[27] Y. Ishibashi, T. Matsui, M. Takeuchi and S. Yamagishis,
“Glucagon-Like Peptide-1 (GLP-1) Inhibits Advance
Glycation End Product (AGE)-Induced Up-Regulation of
VCAM-1 mRNA Levels in Endothelial Cells by Sup-
pressing AGE Receptor (RAGE) Expression,” Bioche-
mical and Biophysical Research Communications, Vol.
391, No. 3, 2010, pp. 1405-1408.
http://dx.doi.org/10.1016/j.bbrc.2009.12.075
[28] D. P. Sonne, T. Engstrom and M. Treiman, “Protetive
Effects of GLP-1 Analogues Exendin-4 and GLP-1 (9-36)
Amide against Ischemiareperfusion Injury in Rat Heart,”
Regulatory Peptides, Vol. 146, No. 1-3, 2008, pp. 243-
249. http://dx.doi.org/10.1016/j.regpep.2007.10.001
[29] L. A. Nikoladis, D. Elahi, Y. T. Shen and R. P. Shannon,
“Active Metabolite of GLP-1 Mediates Myocardial Glu-
cose Uptake and Improve Left Ventricular Performance
in Conscious Dogs with Dilated Cariomyopathy,” Heart
and Circulatory Physiology—American Journal of Physi-
ology, Vol. 289, 2005, pp. H2401-H2408.
[30] L. Timmer, J. P. Henriques, D. P. De Klein, J. H. Devries,
H. Kemperman, P. Steendijk, et al., “Exenatide Reduces
Infarcts Size and Improves Cardiac Function in a Porcine
Model of Ischemia and Reperfusion Injury,” Journal of
the American College of Cardiology, Vol. 53, No. 6, 2009,
pp. 501-510. http://dx.doi.org/10.1016/j.jacc.2008.10.033
[31] G. G. Sokos, H. Bolukoglu, J. German, T. Hentosz, G. J.
Magovern, T. D. Maher, D. A. Dean, S. H. Bailey, G.
Marrone, D. H. Benckart, D. Elaine and R. P. Shannon,
“Effect of Glucagon-Like Peptide-1 (GLP1) on Glycemic
Control and Left Ventricular Function in Patients Under-
going Coronary Artery Bypass Grafting,” American Jour-
nal of Cardiology, 2007, pp. 824-829.
[32] M. H. Noyan-Ashraf, M. A. Momen, K. Ban, A. M. Sadi,
Y. Q. Zhou, A. M. Riazi, L. L. Baggio, R. M. Henkelman,
M. Husain and D. J. Drucker, “GLP-1R Agonist Liraglu-
tide Activates Cytoprotective Pathways and Improves
Outcomes after Experimental Myocardial Infaction in
Mice,” Diabetes, Vol. 58, No. 4, 2009, pp. 975-983.
http://dx.doi.org/10.2337/db08-1193